论文部分内容阅读
目前,国际通用的肺癌TNM分期法对肺癌治疗策略的制定和预后的判断有重要意义,但相同TNM分期的预后存在差异可能由于肿瘤微转移所致。利用分子生物学的技术手段和标记物检测肿瘤微转移以及在TNM分期的基础上进行肺癌分子分期,可以弥补TNM分期的不足,使诊断精确到分子水平。依据肺癌分子分期,制定规范化的治疗方案,对于降低肿瘤复发、转移及改善预后有重要意义。
At present, the international common TNM staging method for lung cancer is of great significance for the formulation of the treatment strategy and prognosis of lung cancer, but the difference in the prognosis of the same TNM staging may be due to the micrometastasis of the tumor. Detection of micrometastases using molecular biological techniques and markers and molecular staging of lung cancer on the basis of TNM staging can make up for the lack of TNM staging and make the diagnosis accurate to the molecular level. According to the molecular staging of lung cancer, to develop a standardized treatment program for reducing tumor recurrence, metastasis and improve prognosis of great significance.